Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 24fludarabine phosphate 22Filgrastim 15Gemcitabine 14fludarabine 13Rituximab 13Brentuximab Vedotin 13Peripheral Blood Stem Cell Transplantation 12Whole-Body Irradiation 11Vorinostat 11Tacrolimus 11Bortezomib 10Mycophenolic Acid 9Melphalan 9Etoposide 9Busulfan 9Sirolimus 8Lenalidomide 8Azacitidine 8Nivolumab 7Dexamethasone 7pembrolizumab 6Radiotherapy 6Cytarabine 6Antilymphocyte Serum 6romidepsin 5aldesleukin 5Panobinostat 5Leucovorin 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hodgkin Disease × carmustine, poliferprosan 20 drug combination × Clear all
NCT02343666 2018-11-20

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

Fred Hutchinson Cancer Center

Phase 1 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡